PLTP

Summary

PLTP (phospholipid transfer protein, HGNC:9093) is a protein-coding gene on chromosome 20q13.12, encoding Phospholipid transfer protein (P55058). Mediates the transfer of phospholipids and free cholesterol from triglyceride-rich lipoproteins (low density lipoproteins or LDL and very low density lipoproteins or VLDL) into high-density lipoproteins (HDL) as well as the exchange of phospholipids between triglyceride-rich lip….

The protein encoded by this gene is one of at least two lipid transfer proteins found in human plasma. The encoded protein transfers phospholipids from triglyceride-rich lipoproteins to high density lipoprotein (HDL). In addition to regulating the size of HDL particles, this protein may be involved in cholesterol metabolism. At least two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 5360 — RefSeq curated summary.

At a glance

• GWAS associations: 91 (top 1% of genes corpus-wide)
• Clinical variants (ClinVar): 234 total
• GTEx eGene: eQTL in 42 tissues, sQTL in 38 (q < 0.05)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.00 (unconstrained)
• MANE Select transcript: NM_006227
• Notable: 234 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9093
Approved symbol	PLTP
Name	phospholipid transfer protein
Location	20q13.12
Locus type	gene with protein product
Status	Approved
Aliases	BPIFE
Ensembl gene	ENSG00000100979
Ensembl biotype	protein_coding
OMIM	172425
Entrez	5360

Gene structure

Transcript identifiers

Ensembl transcripts: 38 — 28 protein_coding, 10 nonsense_mediated_decay

MANE Select: ENST00000372431

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 3, TSL 2: 2

ENST00000372431, ENST00000354050, ENST00000372420, ENST00000420868, ENST00000477313, ENST00000867284, ENST00000867285, ENST00000867286, ENST00000867287, ENST00000867288, ENST00000867289, ENST00000932731, ENST00000932732, ENST00000932733, ENST00000932734, ENST00000932735, ENST00000932736, ENST00000958184, ENST00000958185, ENST00000958186, ENST00000958187, ENST00000958188, ENST00000958189, ENST00000958190, ENST00001008031, ENST00001025083, ENST00001025084, ENST00001025085, ENST00001025086, ENST00001025087, ENST00001025088, ENST00001025089, ENST00001025090, ENST00001025093, ENST00001025095, ENST00001025096, ENST00001112415, ENST00001132729

RefSeq mRNA: 4 — MANE Select: NM_006227 NM_001242920, NM_001242921, NM_006227, NM_182676

CCDS: CCDS13386, CCDS13387, CCDS56196, CCDS56197

Canonical transcript exons

ENST00000372431 — 16 exons

Exon	Start	End
ENSE00000662442	45899462	45899538
ENSE00000662443	45899622	45899685
ENSE00000662444	45899836	45899878
ENSE00000662446	45904800	45904859
ENSE00000662447	45904942	45905118
ENSE00000662448	45906268	45906359
ENSE00000662449	45907692	45907755
ENSE00000662450	45907841	45907904
ENSE00000662451	45909516	45909671
ENSE00000662453	45911152	45911251
ENSE00000845074	45902267	45902334
ENSE00000845075	45902440	45902604
ENSE00000845076	45911353	45911463
ENSE00001432112	45912079	45912155
ENSE00003539934	45909942	45910070
ENSE00003843114	45898622	45899063

Expression profiles

Bgee: expression breadth ubiquitous, 276 present calls, max score 99.04.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 61.4563 / max 1982.3213, expressed in 1488 samples.

Highest expression (Bgee): coronary artery, adrenal gland cortex, mucosa of stomach, adrenal gland, gall bladder.

Genetic regulation across tissues (GTEx eQTL / sQTL)

PLTP is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 42 tissues and its splicing (sQTL) in 38 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 80 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Esophagus Mucosa	eqtl	1.3e-37	-0.72	20:45912327:A:AC
Skin Not Sun Exposed Suprapubic	eqtl	5.9e-35	-0.77	20:45912327:A:AC
Skin Sun Exposed Lower leg	eqtl	5.3e-33	-0.64	20:45912327:A:AC
Adipose Subcutaneous	sqtl	2.3e-28	-0.61	20:45909788:T:C
Adipose Visceral Omentum	sqtl	5.9e-28	-0.71	20:45909788:T:C
Muscle Skeletal	eqtl	9.0e-23	+0.27	20:45919331:C:T
Breast Mammary Tissue	sqtl	1.8e-21	-0.63	20:45909788:T:C
Nerve Tibial	eqtl	7.7e-21	+0.33	20:45916409:C:T
Artery Aorta	eqtl	5.5e-19	+0.35	20:45919331:C:T
Artery Tibial	eqtl	2.0e-18	+0.25	20:45922940:C:T
Lung	sqtl	1.0e-17	-0.62	20:45909788:T:C
Esophagus Muscularis	eqtl	3.2e-17	+0.28	20:45919331:C:T
Colon Sigmoid	eqtl	5.6e-17	+0.37	20:45919331:C:T
Nerve Tibial	sqtl	5.8e-16	-0.52	20:45909788:T:C
Artery Tibial	sqtl	9.8e-16	-0.61	20:45909845:G:T
Adipose Visceral Omentum	eqtl	1.8e-15	+0.26	20:45919331:C:T
Adipose Subcutaneous	eqtl	3.2e-15	+0.25	20:45919331:C:T
Thyroid	eqtl	5.3e-15	+0.27	20:45916409:C:T
Skin Sun Exposed Lower leg	sqtl	2.3e-14	-0.51	20:45909788:T:C
Colon Transverse	eqtl	2.7e-14	-0.36	20:45916308:T:C

FANTOM5 promoters

7 alternative TSS:

Promoter ID	TPM avg	Samples expressed
187515	59.8544	1448
187509	0.5372	176
187514	0.3520	139
187511	0.2793	127
187510	0.1734	70
187513	0.1387	75
187512	0.1214	52

Top tissues by expression

showing 100 of 292 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right coronary artery	UBERON:0001625	99.04	gold quality
right adrenal gland cortex	UBERON:0035827	98.81	gold quality
mucosa of stomach	UBERON:0001199	98.74	gold quality
right adrenal gland	UBERON:0001233	98.70	gold quality
gall bladder	UBERON:0002110	98.56	gold quality
right ovary	UBERON:0002118	98.41	gold quality
omental fat pad	UBERON:0010414	98.38	gold quality
peritoneum	UBERON:0002358	98.33	gold quality
endocervix	UBERON:0000458	98.31	gold quality
body of pancreas	UBERON:0001150	98.31	gold quality
left adrenal gland	UBERON:0001234	98.27	gold quality
coronary artery	UBERON:0001621	98.16	gold quality
left ovary	UBERON:0002119	98.16	gold quality
left coronary artery	UBERON:0001626	98.12	gold quality
left adrenal gland cortex	UBERON:0035825	98.06	gold quality
decidua	UBERON:0002450	97.95	gold quality
thymus	UBERON:0002370	97.93	gold quality
adipose tissue of abdominal region	UBERON:0007808	97.90	gold quality
adrenal cortex	UBERON:0001235	97.83	gold quality
left uterine tube	UBERON:0001303	97.66	gold quality
adrenal gland	UBERON:0002369	97.61	gold quality
stromal cell of endometrium	CL:0002255	97.41	gold quality
ectocervix	UBERON:0012249	97.20	gold quality
thoracic aorta	UBERON:0001515	97.12	gold quality
ascending aorta	UBERON:0001496	97.05	gold quality
body of uterus	UBERON:0009853	97.03	gold quality
descending thoracic aorta	UBERON:0002345	96.85	gold quality
smooth muscle tissue	UBERON:0001135	96.81	gold quality
placenta	UBERON:0001987	96.63	gold quality
synovial joint	UBERON:0002217	96.62	gold quality
right atrium auricular region	UBERON:0006631	96.61	gold quality
subcutaneous adipose tissue	UBERON:0002190	96.60	gold quality
trachea	UBERON:0003126	96.47	gold quality
layer of synovial tissue	UBERON:0007616	96.46	gold quality
right uterine tube	UBERON:0001302	96.34	gold quality
pericardium	UBERON:0002407	96.30	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	96.26	gold quality
cardiac atrium	UBERON:0002081	96.22	gold quality
apex of heart	UBERON:0002098	96.09	gold quality
metanephros cortex	UBERON:0010533	95.97	gold quality
adipose tissue	UBERON:0001013	95.83	gold quality
pigmented layer of retina	UBERON:0001782	95.78	gold quality
cauda epididymis	UBERON:0004360	95.77	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.70	gold quality
upper lobe of left lung	UBERON:0008952	95.53	gold quality
body of stomach	UBERON:0001161	95.52	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.51	gold quality
lower esophagus	UBERON:0013473	95.49	gold quality
right lung	UBERON:0002167	95.47	gold quality
adrenal tissue	UBERON:0018303	95.24	gold quality
myometrium	UBERON:0001296	95.22	gold quality
connective tissue	UBERON:0002384	95.09	gold quality
ovary	UBERON:0000992	94.97	gold quality
aorta	UBERON:0000947	94.94	gold quality
amygdala	UBERON:0001876	94.94	gold quality
upper lobe of lung	UBERON:0008948	94.93	gold quality
nucleus accumbens	UBERON:0001882	94.75	gold quality
skin of leg	UBERON:0001511	94.69	gold quality
fundus of stomach	UBERON:0001160	94.39	gold quality
tibial nerve	UBERON:0001323	94.39	gold quality
caudate nucleus	UBERON:0001873	94.38	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.32	gold quality
vagina	UBERON:0000996	94.25	gold quality
heart	UBERON:0000948	94.19	gold quality
skin of abdomen	UBERON:0001416	94.18	gold quality
stomach	UBERON:0000945	94.16	gold quality
superficial temporal artery	UBERON:0001614	93.98	gold quality
minor salivary gland	UBERON:0001830	93.95	gold quality
vena cava	UBERON:0004087	93.91	gold quality
hypothalamus	UBERON:0001898	93.90	gold quality
urinary bladder	UBERON:0001255	93.78	gold quality
small intestine Peyer’s patch	UBERON:0003454	93.70	gold quality
lymph node	UBERON:0000029	93.69	gold quality
heart left ventricle	UBERON:0002084	93.64	gold quality
vermiform appendix	UBERON:0001154	93.63	gold quality
saliva-secreting gland	UBERON:0001044	93.53	gold quality
cardiac ventricle	UBERON:0002082	93.44	gold quality
popliteal artery	UBERON:0002250	93.38	gold quality
cranial nerve II	UBERON:0000941	93.37	gold quality
tibial artery	UBERON:0007610	93.37	gold quality
zone of skin	UBERON:0000014	93.35	gold quality
putamen	UBERON:0001874	93.27	gold quality
caecum	UBERON:0001153	93.26	gold quality
mammalian vulva	UBERON:0000997	93.25	gold quality
transverse colon	UBERON:0001157	93.25	gold quality
esophagus	UBERON:0001043	93.23	gold quality
ventricular zone	UBERON:0003053	93.23	gold quality
caput epididymis	UBERON:0004358	93.07	gold quality
right frontal lobe	UBERON:0002810	92.81	gold quality
saphenous vein	UBERON:0007318	92.61	gold quality
right lobe of thyroid gland	UBERON:0001119	92.38	gold quality
mouth mucosa	UBERON:0003729	92.33	gold quality
small intestine	UBERON:0002108	91.95	gold quality
cardiac muscle of right atrium	UBERON:0003379	91.68	gold quality
urethra	UBERON:0000057	91.66	gold quality
spinal cord	UBERON:0002240	91.63	gold quality
left ventricle myocardium	UBERON:0006566	91.56	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	91.53	gold quality
nipple	UBERON:0002030	91.52	gold quality
cingulate cortex	UBERON:0003027	91.44	gold quality

Single-cell (SCXA)

Detected in 18 experiment(s), a significant marker in 18.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	4908.27
E-MTAB-6678	yes	4263.25
E-GEOD-84465	yes	3251.42
E-MTAB-6701	yes	2592.28
E-GEOD-124472	yes	1900.71
E-CURD-79	yes	1725.80
E-MTAB-6911	yes	521.53
E-MTAB-8142	yes	44.00
E-MTAB-10553	yes	42.94
E-HCAD-5	yes	32.89
E-MTAB-10287	yes	22.35
E-GEOD-81547	yes	21.99
E-HCAD-10	yes	20.60
E-GEOD-93593	yes	16.82
E-CURD-112	yes	16.70

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 76 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Adipose tissue	tissue	409.2	not detected
Placenta	tissue	402.9	not detected
Urinary bladder	tissue	316.2	not detected
Choroid plexus	tissue	299.7
Pancreas	tissue	279.9	not detected
Superior colliculi	tissue	270.2
Substantia nigra	tissue	225.5
Thymus	tissue	214.2
Periaqueductal gray	tissue	203.9
Spinal cord	tissue	201.0
Hypothalamus	tissue	184.4
Medulla oblongata	tissue	180.9
Gallbladder	tissue	170.7	not detected
Smooth muscle	tissue	169.8	not detected
Pons	tissue	164.2
Midbrain	tissue	152.1
Septum	tissue	150.9
Thalamus	tissue	142.2
Hippocampal formation	tissue	139.7
Ovary	tissue	136.1	not detected
Salivary gland	tissue	124.3	not detected
Cervix	tissue	119.2	not detected
Ventral forebrain	tissue	116.6
Amygdala	tissue	114.5
Corpus callosum	tissue	112.0
Vagina	tissue	106.0	not detected
Basal ganglia	tissue	105.9	not detected
Entorhinal cortex	tissue	105.9
Putamen	tissue	104.5
Caudate putamen	tissue	98.1
Adrenal gland	tissue	91.9	not detected
Cerebral cortex	tissue	87.9	not detected
Temporal cortex	tissue	87.9
Motor cortex	tissue	83.9
Hippocampus	tissue	82.0	not detected
Frontal cortex	tissue	78.7
Insular cortex	tissue	78.5
Prefrontal cortex	tissue	77.1
Olfactory bulb	tissue	76.8
Appendix	tissue	75.7	not detected
Retrosplenial cortex	tissue	73.7
Fallopian tube	tissue	72.7	not detected
Nucleus accumbens	tissue	72.5
Locus coeruleus	tissue	69.8
Retrosplenial and cingulate cortex	tissue	69.5
Epididymis	tissue	68.6	not detected
Somatosensory cortex	tissue	68.4
Seminal vesicle	tissue	67.5	not detected
Endometrium 1	tissue	66.3	not detected
Occipital cortex	tissue	63.5
Skin 1	tissue	60.3	not detected
Esophagus	tissue	58.2	not detected
Lymph node	tissue	57.4	not detected
Cerebellum	tissue	57.2	not detected
Heart muscle	tissue	53.1	not detected
Lung	tissue	49.4	not detected
Colon	tissue	44.1	not detected
Breast	tissue	43.2	not detected
Rectum	tissue	39.8	not detected
Postcentral gyrus	tissue	39.4

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Periaquaductal grey, lateral (206.4), Ventral spinal cord (201.0), Dorsal spinal cord (192.4), Blood vessel (169.7), Dorsal raphe nucleus (162.7).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXO1, GLI1, NR0B2, NR1H2, NR1H3, NR1H4, TCF3

miRNA regulators (miRDB)

Targeting PLTP by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

18 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-378A-5P	99.65	66.33	1311
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-3140-5P	99.39	69.04	1136
HSA-MIR-3191-5P	99.24	66.52	1722
HSA-MIR-6803-5P	99.19	63.90	1026
HSA-MIR-7151-3P	99.04	69.72	2370
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-6728-3P	98.63	67.63	1534
HSA-MIR-7114-5P	98.51	67.87	1349
HSA-MIR-615-5P	98.10	63.76	591
HSA-MIR-891A-3P	98.05	67.99	970
HSA-MIR-1322	97.98	68.96	625
HSA-MIR-4438	97.96	63.70	947
HSA-MIR-6737-5P	97.75	66.54	1044
HSA-MIR-299-3P	97.73	66.67	773
HSA-MIR-1225-5P	96.76	66.85	417
HSA-MIR-184	94.24	64.40	152

Functional genomics

gnomAD constraint: pLI 2.85e-12, LOEUF 1, missense Z 0.888 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000372431 — one region, missense o/e 0.94.

Literature-anchored findings (GeneRIF, showing 40)

• Human PLTP expressed in plasma from transgenic mice contributes to the formation of pre beta-HDL, whereas the expression of human cholesterol ester transfer protein does not affect this process. (PMID:11716766)
• This protein and pre-beta-high density lipoprotein are degraded by mast cell chymase, the high affinity efflux of cholesterol from macrophage foam cells is impaired. (PMID:12531890)
• The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. (PMID:12612088)
• Elevation of PLTP activity results in rapid disposal of cholesterol from the body via increased conversion into bile acids and subsequent excretion. (PMID:12649089)
• PLTP is expressed by macrophages, is regulated by cholesterol loading, and is present in atherosclerotic lesions (PMID:12730304)
• elevated PLTP activity in hypertriglyceridemia is related to insulin resistance and not to increased PLTP mass (PMID:12754275)
• HepG2-derived PLTP resembles in several aspects the high-activity form of PLTP found in human plasma (PMID:12810820)
• PLTP is present in human atherosclerotic lesions, and its distribution suggests roles for PLTP in both cellular cholesterol metabolism and lipoprotein retention on extracellular matrix (PMID:12835223)
• seminal PLTP concentrations represented 25% of the concentration measured in blood plasma; seminal PLTP activity was partially associated with prostasomes; higher PLTP activity was measured in seminal plasma samples with low seminal vesicle secretions (PMID:12837922)
• PLTP concentration serve as a predictor of Coronary disease, independent of HDL cholesterol, triglycerides and other established risk factors. (PMID:14695459)
• expression of PLTP results in increased atherosclerosis in spite of reduced apoB-containing lipoproteins, by reduction of HDL and of HDL-associated antioxidant enzyme activities (PMID:14993244)
• Phospholipid transfer protein is emerging as a multifaceted and multifunctional player in lipid and lipoprotein metabolism [review]. (PMID:15166780)
• patthophysiologic role of PLTP in decreasing the vitamin E content of apolipoprotein B-containing lipoproteins in Type 2 diabetes. (PMID:15448094)
• A major role for stimulated phospholipid transfer protein (PLTP) activity is identified in the recycling of pre-beta 1-high density lipoprotein during reverse cholesterol transport. (PMID:15544352)
• The findings of reduced PLTP activity in AD CSF, and the observation that PLTP can influence apoE secretion in astrocytes suggest a potential link between alterations in the brain lipid metabolism and AD pathogenesis. (PMID:15795933)
• ApoE proteoliposomes induced a concentration-dependent activation of low-activity form of PLTP. (PMID:15845396)
• Human tear fluid contains catalytically active phospholipid transfer protein (PLTP), which resembles the active form of PLTP present in plasma. (PMID:15924430)
• These findings indicate that PLTP gene variation is an important determinant of plasma lipoproteins and affects disorders of HDL metabolism. (PMID:16388083)
• The increase in PLTP activity in type 2 diabetes is partly related to the changes in apolipoprotein E. (PMID:16389649)
• Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins. (PMID:16520487)
• Association between the decrease in PLTP activity and aapolipoprotein E during statin treatment supports the hypothesis that apoE may prevent PLTP inactivation in diabetes. (PMID:16644710)
• results suggest that secretion-competent PLTP requires glycosylation but that no single glycosylation site is required (PMID:16862459)
• PLTP is capable of transferring lipids by a shuttle mechanism and formation of a ternary complex between PLTP, acceptor, and donor particles is not necessary for phospholipid transfer (PMID:17260960)
• Lipolysis of triglyceride-rich lipoproteins and their remodelling by PLTP interact to disturb cellular phospholipid flux and intracellular signaling processes, ultimately leading to apoptosis in human macrophages and endothelial cells. (PMID:17272752)
• We resequenced candidate genes for HDL regulation and identified several functional nonsynonymous mutations including 1 in phospholipid transfer protein (PLTP), leaving 88% (110/124) of HDL deficient subjects without a genetic diagnosis. (PMID:17303779)
• phospholipid and cholesteryl ester transfer proteins are important in very low and high-density lipoprotein metabolism and display concerted actions in patients with type 2 diabetes [review] (PMID:17495597)
• in non-diabetic, non-smoking subjects low rather than high PLTP activity is a marker for the presence of peripheral arterial disease (PMID:17553507)
• the potential interaction between human plasma phospholipid transfer protein (and apolipoprotein A-I (apoA-I), double transgenic animals (hPLTPtg/hApoAItg) were compared with hApoAItg mice. (PMID:17761633)
• PTLP activity is positively associated with serum ALT1, GOT1 and GOT2 in type 2 diabetes mellitus and metabolic syndrome. (PMID:17877759)
• Cholesterol efflux from macrophage foam cells is enhanced by active PLTP through generation of two types of acceptor particles. (PMID:17900150)
• Increased PLTP activity associated with the impaired cellular cholesterol efflux in type 2 diabetic subjects with coronary artery disease. (PMID:17917406)
• it is concluded that apoE enhances the capacity of PLTP to remodel HDL but reduces the ability of HDL to participate in PLTP-mediated phospholipid transfers. (PMID:17921435)
• ABCA1-dependent cholesterol efflux requires an amphipathic helical region of the N-terminal barrel of phospholipid transfer protein (PMID:18287097)
• Acute elevation of PLTP activity destabilizes atherosclerotic lesions and aggravates pre-existing atherosclerosis. (PMID:18421000)
• Association of rs2294213 with HDL-C levels into the extremes of the HDL distribution. (PMID:19013296)
• Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. (PMID:19100548)
• The results confirm the atherogenic behavior of PLTP in coronary artery disease. (PMID:19135989)
• These findings indicate that plasma HDL level is an important regulator of plasma PLTP and might play a role in the stabilization of PLTP in plasma. (PMID:19422933)
• PLTP activity may represent a novel marker of left ventricular systolic dysfunction in patients with known or suspected coronary artery disease. (PMID:19446293)
• PLTP may be an important modulator of signal transduction pathways in human neurons. (PMID:19472218)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio	pltp	ENSDARG00000104495
mus_musculus	Pltp	ENSMUSG00000017754
rattus_norvegicus	Pltp	ENSRNOG00000016488
caenorhabditis_elegans		WBGENE00003812
caenorhabditis_elegans		WBGENE00008512
caenorhabditis_elegans	F10D11.6	WBGENE00008652
caenorhabditis_elegans		WBGENE00015544
caenorhabditis_elegans		WBGENE00015545
caenorhabditis_elegans		WBGENE00016951
caenorhabditis_elegans		WBGENE00018403
caenorhabditis_elegans		WBGENE00020563
caenorhabditis_elegans		WBGENE00022627

Paralogs (12): BPIFB2 (ENSG00000078898), CETP (ENSG00000087237), BPI (ENSG00000101425), BPIFB1 (ENSG00000125999), LBP (ENSG00000129988), BPIFA2 (ENSG00000131050), BPIFA3 (ENSG00000131059), BPIFB6 (ENSG00000167104), BPIFC (ENSG00000184459), BPIFB3 (ENSG00000186190), BPIFB4 (ENSG00000186191), BPIFA1 (ENSG00000198183)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:103151) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 26 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased circulating HDL cholesterol level	2
abnormal circulating cholesterol level	1
increased circulating LDL cholesterol level	1
impaired fertilization	1
abnormal cornea morphology	1
dry eyes	1
reduced male fertility	1
decreased circulating triglyceride level	1
abnormal caput epididymis morphology	1
abnormal cauda epididymis morphology	1
asthenozoospermia	1
abnormal cellular cholesterol metabolism	1
decreased circulating phospholipid level	1
abnormal sperm physiology	1
abnormal phospholipid level	1
increased circulating VLDL cholesterol level	1
decreased circulating cholesterol level	1
abnormal cornea stroma morphology	1
abnormal cornea epithelium morphology	1
abnormal vitamin E level	1
decreased circulating HDL phospholipid level	1
decreased circulating non-HDL phospholipid level	1
abnormal circulating non-HDL cholesterol level	1
increased cornea epithelium thickness	1
disorganized cornea epithelium	1

+1 more (showing top 25).

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
SPATA25	protein-coding	128497
NEURL2	protein-coding	140825
CTSA	protein-coding	5476
ZNF335	protein-coding	63925
PCIF1	protein-coding	63935
ZSWIM3	protein-coding	140831
ZSWIM1	protein-coding	90204
ACOT8	protein-coding	10005
SNX21	protein-coding	90203
SLC12A5-AS1	ncRNA	109729184
MMP9	protein-coding	4318

Protein

Protein identifiers

Phospholipid transfer protein — P55058 (reviewed: P55058)

Alternative names: Lipid transfer protein II

All UniProt accessions (1): P55058

UniProt curated annotations — full annotation on UniProt →

Function. Mediates the transfer of phospholipids and free cholesterol from triglyceride-rich lipoproteins (low density lipoproteins or LDL and very low density lipoproteins or VLDL) into high-density lipoproteins (HDL) as well as the exchange of phospholipids between triglyceride-rich lipoproteins themselves. Facilitates the transfer of a spectrum of different lipid molecules, including diacylglycerol, phosphatidic acid, sphingomyelin, phosphatidylcholine, phosphatidylinositol, phosphatidylglycerol, cerebroside and phosphatidyl ethanolamine. Plays an important role in HDL remodeling which involves modulating the size and composition of HDL. Also plays a key role in the uptake of cholesterol from peripheral cells and tissues that is subsequently transported to the liver for degradation and excretion. Two distinct forms of PLTP exist in plasma: an active form that can transfer phosphatidylcholine from phospholipid vesicles to HDL, and an inactive form that lacks this capability.

Subcellular location. Secreted. Nucleus.

Tissue specificity. Widely expressed. Highest level of expression in the ovary, thymus and placenta, with moderate levels found in the pancreas, small intestine, testis, lung and prostrate. Low level expression in the kidney, liver and spleen, with very low levels found in the heart, colon, skeletal muscle, leukocytes and brain. Expressed in the cortical neurons.

Post-translational modifications. Glycosylation is necessary for secretion and its phospholipid transfer activity.

Similarity. Belongs to the BPI/LBP/Plunc superfamily. BPI/LBP family.

Isoforms (4)

UniProt ID	Names	Canonical?
P55058-1	1	yes
P55058-2	2
P55058-3	3
P55058-4	4

RefSeq proteins (4): NP_001229849, NP_001229850, NP_006218, NP_872617 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001124	Lipid-bd_serum_glycop_C	Domain
IPR017942	Lipid-bd_serum_glycop_N	Domain
IPR017943	Bactericidal_perm-incr_a/b_dom	Homologous_superfamily
IPR017954	Lipid-bd_serum_glycop_CS	Conserved_site
IPR030675	BPI/LBP	Family
IPR032942	BPI/LBP/Plunc	Family

Pfam: PF01273, PF02886

Catalyzed reactions (Rhea)

• a 1,2-diacyl-sn-glycero-3-phosphate(in) = a 1,2-diacyl-sn-glycero-3-phosphate(out) (RHEA:36435)
• a 1,2-diacyl-sn-glycero-3-phosphocholine(in) = a 1,2-diacyl-sn-glycero-3-phosphocholine(out) (RHEA:38571)
• a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol)(in) = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol)(out) (RHEA:38691)
• a 1,2-diacyl-sn-glycero-3-phosphoethanolamine(in) = a 1,2-diacyl-sn-glycero-3-phosphoethanolamine(out) (RHEA:38895)
• a 1,2-diacyl-sn-glycerol(in) = a 1,2-diacyl-sn-glycerol(out) (RHEA:39723)
• a sphingomyelin(in) = a sphingomyelin(out) (RHEA:39727)
• a 1,2-diacyl-sn-glycero-3-phospho-(1’-sn-glycerol)(in) = a 1,2-diacyl-sn-glycero-3-phospho-(1’-sn-glycerol)(out) (RHEA:39743)
• 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine(in) = 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine(out) (RHEA:46488)
• 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine(in) = 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine(out) (RHEA:46492)
• N-(hexadecanoyl)-sphing-4-enine-1-phosphocholine(in) = N-(hexadecanoyl)-sphing-4-enine-1-phosphocholine(out) (RHEA:46496)

UniProt features (33 total): mutagenesis site 11, sequence variant 7, glycosylation site 6, splice variant 3, sequence conflict 3, signal peptide 1, chain 1, disulfide bond 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P55058-F1	89.36	0.71

Human Protein Atlas

Protein class: Transporters, Transporter channels and pores, Predicted secreted proteins, Predicted intracellular proteins, Plasma proteins

Protein evidence: Evidence at protein level

Antibody reliability (HPA): IH approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1)

Type	Positions
Disulfide bond	146–185

Glycosylation sites (6)

Type	Positions
N-linked (glcnac…) (complex) asparagine	64, 117, 245
N-linked (glcnac…) asparagine	94, 143, 398

Mutagenesis-validated functional residues (11)

Position	Phenotype
64	increased nuclear localization; when associated with a-94; a-117 and a-143.
66	significant reduction in phospholipid transfer activity. no effect on secretion.
94	increased nuclear localization; when associated with a-64; a-117 and a-143.
96	significant reduction in phospholipid transfer activity. increased secretion.
117	increased nuclear localization; when associated with a-64; a-94 and a-143.
119	significant reduction in phospholipid transfer activity. increased secretion.
143	increased nuclear localization; when associated with a-64; a-94 and a-117.
145	significant reduction in phospholipid transfer activity. reduced secretion.
176	significant reduction in hdl-binding and absence of lipid transfer activity.
247	significant reduction in phospholipid transfer activity. reduced secretion.
400	significant reduction in phospholipid transfer activity. reduced secretion.

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 2; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

2 pathways:

ID	Pathway	Evidence
R-HSA-8964058	HDL remodeling	curated
R-HSA-9029569	NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	curated

MSigDB gene sets: 288 (showing top): TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, WALLACE_PROSTATE_CANCER_RACE_UP, CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN, MODULE_151, SP3_Q3, GOBP_POSITIVE_REGULATION_OF_CHOLESTEROL_EFFLUX, GOBP_REGULATION_OF_CHOLESTEROL_EFFLUX, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, GOBP_POSITIVE_REGULATION_OF_STEROL_TRANSPORT, RIZKI_TUMOR_INVASIVENESS_3D_DN, GOBP_POSITIVE_REGULATION_OF_LIPID_TRANSPORT, GOBP_ORGANIC_HYDROXY_COMPOUND_TRANSPORT, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, GOBP_CHOLESTEROL_EFFLUX, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP

GO Biological Process (9): lipid metabolic process (GO:0006629), lipid transport (GO:0006869), positive regulation of cholesterol efflux (GO:0010875), phospholipid transport (GO:0015914), high-density lipoprotein particle remodeling (GO:0034375), ceramide transport (GO:0035627), glycolipid transport (GO:0046836), sterol transport (GO:0015918), intermembrane lipid transfer (GO:0120009)

GO Molecular Function (22): high-density lipoprotein particle binding (GO:0008035), phosphatidylethanolamine binding (GO:0008429), phosphatidylinositol transfer activity (GO:0008526), diacylglycerol binding (GO:0019992), low-density lipoprotein particle binding (GO:0030169), phosphatidylcholine binding (GO:0031210), very-low-density lipoprotein particle binding (GO:0034189), phosphatidic acid binding (GO:0070300), ceramide binding (GO:0097001), phospholipid transfer activity (GO:0120014), ceramide transfer activity (GO:0120017), phosphatidylcholine transfer activity (GO:0120019), cholesterol transfer activity (GO:0120020), diacylglyceride transfer activity (GO:0140337), sphingomyelin transfer activity (GO:0140338), phosphatidylglycerol transfer activity (GO:0140339), cerebroside transfer activity (GO:0140340), phosphatidylglycerol binding (GO:1901611), phosphatidylethanolamine transfer activity (GO:1904121), phosphatidic acid transfer activity (GO:1990050), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (3): extracellular region (GO:0005576), nucleus (GO:0005634), high-density lipoprotein particle (GO:0034364)

Reactome top-level categories

2 top-level categories:

Category	Pathways
Plasma lipoprotein remodeling	1
NR1H2 and NR1H3-mediated signaling	1

GO top-level categories

35 GO namespaces:

Category	Terms
lipid transport	5
phospholipid binding	5
phospholipid transfer activity	5
lipoprotein particle binding	3
lipid transfer activity	3
anion binding	2
sphingolipid transfer activity	2
primary metabolic process	1
transport	1
lipid localization	1
regulation of cholesterol efflux	1
positive regulation of cholesterol transport	1
cholesterol efflux	1
organophosphate ester transport	1
plasma lipoprotein particle remodeling	1
nitrogen compound transport	1
carbohydrate derivative transport	1
organic hydroxy compound transport	1
membrane organization	1
phosphatidylinositol binding	1
lipid binding	1
cation binding	1
quaternary ammonium group binding	1
protein binding	1
sphingolipid binding	1
phospholipid transport	1
ceramide binding	1
phosphatidylcholine binding	1
cholesterol binding	1
sterol transfer activity	1
glycolipid transfer activity	1
ceramide transfer activity	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1
plasma lipoprotein particle	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 26 of 35 annotations. The rest are phylogenetic / computational / electronic (IEA).

26 experimentally-supported GO terms:

GO term	NS	Evidence
ceramide transport	BP	direct assay
glycolipid transport	BP	direct assay
high-density lipoprotein particle remodeling	BP	direct assay
lipid transport	BP	direct assay
phospholipid transport	BP	direct assay
positive regulation of cholesterol efflux	BP	direct assay
extracellular region	CC	direct assay
high-density lipoprotein particle	CC	direct assay
nucleus	CC	direct assay
ceramide binding	MF	direct assay
cerebroside transfer activity	MF	direct assay
diacylglyceride transfer activity	MF	direct assay
diacylglycerol binding	MF	direct assay
high-density lipoprotein particle binding	MF	direct assay
low-density lipoprotein particle binding	MF	direct assay
phosphatidic acid binding	MF	direct assay
phosphatidic acid transfer activity	MF	direct assay
phosphatidylcholine binding	MF	direct assay
phosphatidylcholine transfer activity	MF	direct assay
phosphatidylethanolamine binding	MF	direct assay
phosphatidylethanolamine transfer activity	MF	direct assay
phosphatidylglycerol binding	MF	direct assay
phosphatidylglycerol transfer activity	MF	direct assay
phospholipid transfer activity	MF	direct assay
sphingomyelin transfer activity	MF	direct assay
very-low-density lipoprotein particle binding	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 1,142 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLTP	APOA1	P02647	846
PLTP	BPIFA1	Q9NP55	825
PLTP	APOB	P04114	806
PLTP	LPL	P06858	749
PLTP	LCAT	P04180	737
PLTP	SCARB1	Q8WTV0	729
PLTP	LIPC	P11150	728
PLTP	ABCA1	O95477	715
PLTP	NPC1L1	Q9UHC9	713
PLTP	ABCG1	P45844	688
PLTP	CYP7A1	P22680	680
PLTP	APOA2	P02652	676
PLTP	LIPG	Q9Y5X9	654
PLTP	APOE	P02649	650
PLTP	APOD	P05090	640

IntAct

Human interaction partners of PLTP in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

4 partners by confidence:

Partner	Interaction type	MIscore	Records
SEL1L3	association	0.530	1
CREB3	physical association	0.490	2
CANX	association	0.350	1
CLGN	association	0.350	1

BioGRID (88 interactions; top human partners by supporting records): ADPGK (Affinity Capture-MS; 3 records), CANX (Affinity Capture-MS; 3 records), DHFRL1 (Affinity Capture-MS; 3 records), EPB41L5 (Affinity Capture-MS; 3 records), FAM69A (Affinity Capture-MS; 3 records), GLB1L2 (Affinity Capture-MS; 3 records), SEL1L3 (Affinity Capture-MS; 3 records), UGT8 (Affinity Capture-MS; 3 records), APOA1 (Reconstituted Complex; 2 records), APOA2 (Reconstituted Complex; 2 records), CLGN (Affinity Capture-MS; 2 records), DDX31 (Affinity Capture-MS; 2 records), DPEP2 (Affinity Capture-MS; 2 records), FUT10 (Affinity Capture-MS; 2 records), GALNT7 (Affinity Capture-MS; 2 records)

Disease & clinical

Genetic variants

Variant evidence for PLTP: 234 ClinVar records (0 pathogenic / likely pathogenic); 91 GWAS associations.

ClinVar

234 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	134
Likely benign	69
Benign	13

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 37 predictions of 1,230):

Position(s)	Effect	Δscore	Sites
20:45899460–45899461	donor_loss	1.0000	5
20:45899539–45899540	acceptor_loss	1.0000	6
20:45899620–45899621	donor_loss	1.0000	3
20:45899686–45899687	acceptor_loss	1.0000	6
20:45899697	acceptor_gain	1.0000
20:45902265–45902266	donor_loss	1.0000	5
20:45902335–45902336	acceptor_loss	1.0000	5
20:45902339	acceptor_gain	1.0000
20:45902345	acceptor_gain	1.0000
20:45902438–45902439	donor_loss	1.0000	4

AlphaMissense

818 missense substitutions predicted likely pathogenic (of 3,188 scored), across 273 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M263	9	0.831	0.975
F101	8	0.872	0.976
D112	8	0.862	0.905
F234	8	0.854	0.966
F464	8	0.852	0.964
F157	8	0.788	0.948
C146	7	0.982	0.991
C185	7	0.981	0.989
D216	7	0.906	0.952
F455	7	0.893	0.986
F41	7	0.882	0.970
F238	7	0.849	0.974
F393	7	0.827	0.947
F82	7	0.818	0.905
F239	7	0.810	0.942
F273	7	0.794	0.885
D461	7	0.723	0.809
G236	6	0.892	0.974
R103	6	0.890	0.962
D210	6	0.877	0.939

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

4 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	unfavorable	3.07e-08
Kidney Renal Clear Cell Carcinoma (validation)	unfavorable	3.18e-06
Glioblastoma Multiforme (validation)	unfavorable	0.000367
Stomach Adenocarcinoma (TCGA)	unfavorable	0.000506

Disease associations

OMIM: gene MIM:172425 | disease phenotypes:

GWAS associations

showing 30 of 91 associations:

Study	Trait	p-value
GCST010242_58	HDL cholesterol levels	7e-143
GCST010244_339	Triglyceride levels	2e-109
GCST008084_144	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	1e-69
GCST010243_110	Apolipoprotein B levels	1e-59
GCST008084_9	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	6e-57
GCST008075_72	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	8e-56
GCST000533_14	Lipid metabolism phenotypes	3e-49
GCST000533_17	Lipid metabolism phenotypes	1e-45
GCST008075_214	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	2e-45
GCST008083_38	Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	8e-44
GCST008074_32	Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	1e-43
GCST001639_6	Metabolite levels	2e-42
GCST000533_15	Lipid metabolism phenotypes	4e-40
GCST002223_52	HDL cholesterol	5e-40
GCST004232_72	HDL cholesterol levels	6e-39
GCST000533_16	Lipid metabolism phenotypes	8e-37
GCST002216_4	Triglycerides	2e-34
GCST001392_3	Lipid metabolism phenotypes	2e-31
GCST003680_10	C-reactive protein levels or HDL-cholesterol levels (pleiotropy)	5e-29
GCST008074_101	Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	5e-27
GCST008085_173	HDL cholesterol levels in current drinkers	9e-27
GCST008083_10	Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	2e-26
GCST011348_39	High density lipoprotein cholesterol levels	2e-25
GCST003681_11	C-reactive protein levels or triglyceride levels (pleiotropy)	2e-24
GCST011345_37	Triglyceride levels	3e-24
GCST000755_34	HDL cholesterol	2e-22
GCST008087_65	Triglyceride levels in current drinkers	3e-22
GCST010241_40	Apolipoprotein A1 levels	1e-21
GCST002897_9	Triglycerides	9e-21
GCST008070_62	HDL cholesterol levels	8e-20

EFO canonical traits (from GWAS)

13 canonical traits:

EFO ID	Trait name
EFO:0004530	triglyceride measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004529	lipid measurement
EFO:0004723	coronary artery calcification
EFO:0004458	C-reactive protein measurement
EFO:0007874	gut microbiome measurement
EFO:0007660	neuroticism measurement
EFO:0008475	mood instability measurement
EFO:0004329	alcohol drinking
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004615	apolipoprotein B measurement
EFO:0004533	alkaline phosphatase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5962 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

15 measured of 15 human assays (15 total across all organisms); most potent 15 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
N-(4,5-diphenyl-1,3-selenazol-2-yl)-3,4-dihydroxybenzamide	IC50	8000 nM
N-(5-butyl-4-(4-hydroxyphenyl)-1,3-selenazol-2-yl)-3,4,5-trihydroxybenzamide	IC50	10000 nM
N-(5-benzyl-4-(4-hydroxyphenyl)-1,3-selenazol-2-yl)hexanamide	IC50	25000 nM
N-(4,5-diphenyl-1,3-selenazol-2-yl)-3,4,5-trihydroxybenzamide	IC50	25000 nM
N-(5-benzyl-4-(4-methoxyphenyl)-1,3-selenazol-2-yl)-3,4-dimethoxybenzamide	IC50	30000 nM
N-(5-ethyl-4-(4-hydroxyphenyl)-1,3-selenazol-2-yl)-3,4,5-trihydroxybenzamide	IC50	32000 nM
N-(5-benzyl-4-(4-hydroxyphenyl)-1,3-selenazol-2-yl)-3,4,5-trihydroxybenzamide	IC50	32000 nM
N-(5-benzyl-4-(4-hydroxyphenyl)-1,3-selenazol-2-yl)-3,4-dihydroxybenzamide	IC50	35000 nM
4-chloro-N-(5-ethyl-4-(4-hydroxyphenyl)-1,3-selenazol-2-yl)benzamide	IC50	60000 nM
N-(5-butyl-4-(4-hydroxyphenyl)-1,3-selenazol-2-yl)acetamide	IC50	60000 nM
N-(5-butyl-4-(4-hydroxyphenyl)-1,3-selenazol-2-yl)-4-chlorobenzamide	IC50	60000 nM
N-(5-butyl-4-(4-methoxyphenyl)-1,3-selenazol-2-yl)-3,4-dimethoxybenzamide	IC50	80000 nM
N-(5-benzyl-4-(4-methoxyphenyl)-1,3-selenazol-2-yl)-4-nitrobenzamide	IC50	85000 nM
N-(5-ethyl-4-(4-methoxyphenyl)-1,3-selenazol-2-yl)-3,4-dimethoxybenzamide	IC50	100000 nM
N-(5-butyl-4-(4-methoxyphenyl)-1,3-selenazol-2-yl)-3,4,5-trimethoxybenzamide	IC50	150000 nM

ChEMBL bioactivities

2 potent at pChembl≥5 of 40 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.10	IC50	8000	nM	CHEMBL1222668
5.00	IC50	1e+04	nM	CHEMBL1222737

PubChem BioAssay actives

2 with measured affinity, of 23 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-(4,5-diphenyl-1,3-selenazol-2-yl)-3,4-dihydroxybenzamide	501651: Inhibition of PLTP	ic50	8.0000	uM
N-[5-butyl-4-(4-hydroxyphenyl)-1,3-selenazol-2-yl]-3,4,5-trihydroxybenzamide	501651: Inhibition of PLTP	ic50	10.0000	uM

CTD chemical–gene interactions

63 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	6
Benzo(a)pyrene	increases expression, affects methylation, decreases methylation	5
bisphenol A	decreases expression, increases expression, affects cotreatment	3
Aflatoxin B1	affects expression, increases expression	3
entinostat	increases expression, affects cotreatment	2
Tobacco Smoke Pollution	affects expression, decreases expression	2
Tretinoin	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
2,4,6-tribromophenol	increases expression	1
triphenyl phosphate	affects expression	1
decabromobiphenyl ether	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	increases expression	1
tetrabromobisphenol A	increases expression	1
periodate-oxidized adenosine	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
JP8 aviation fuel	decreases expression	1
chloropicrin	increases expression	1
T0901317	increases expression	1
GW 501516	affects binding, increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
candoxin	decreases expression	1
obeticholic acid	decreases expression	1
GW 3965	increases expression	1
ICG 001	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
pentabrominated diphenyl ether 100	increases expression	1

ChEMBL screening assays

10 unique, capped per target: 10 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1015039	Binding	Inhibition of PLTP activity assessed as phosphatidylcholine transferred from [3H]phosphatidylcholine (dipalmitoyl)-labeled liposomes to HDL by cell based liquid scintillation counter	Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor. — *J Med Chem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for PLTP across ~30M SureChEMBL compounds — explore on Sugi Predict.